glp-1 gastric intestinal obstruction legal team in kentucky class action law office glp -1 digestive blockage kentucky Pharmaceutical giant Novo Nordisk is – kentucky semaglutide digestive blockage class

Now, leading medical organizations like the World Health Organization recognize obesity as a chronic medical condition that can drive numerous other health ailments such as diabetes, heart disease, kidney disease and potentially even cancer

50 , D1522d1527 (2022)

[Accessed on 11 June 2026] Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial (2023)

The data showed a modestly reduced risk of depression with GLP-1RAs when compared with DPP4is and a negligible difference in depression risk between GLP-1RAs and SGLT2is